HC Wainwright set a $2.00 price target on Advaxis (NASDAQ:ADXS) in a research report report published on Tuesday. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, ValuEngine upgraded shares of Advaxis from a hold rating to a buy rating in a report on Thursday, November 1st.

NASDAQ:ADXS traded down $0.03 on Tuesday, hitting $0.55. The stock had a trading volume of 283,998 shares, compared to its average volume of 644,991. The firm has a market capitalization of $30.81 million, a price-to-earnings ratio of -0.24 and a beta of 2.52. Advaxis has a 1-year low of $0.47 and a 1-year high of $3.58.

Advaxis (NASDAQ:ADXS) last posted its earnings results on Monday, September 10th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The firm had revenue of $1.13 million during the quarter, compared to analyst estimates of $1.85 million. Advaxis had a negative net margin of 1,062.68% and a negative return on equity of 165.23%. Sell-side analysts anticipate that Advaxis will post -1.09 EPS for the current year.

In other Advaxis news, Director Roni Appel bought 33,333 shares of the business’s stock in a transaction that occurred on Tuesday, September 11th. The shares were purchased at an average cost of $1.20 per share, with a total value of $39,999.60. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.21% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in ADXS. BlackRock Inc. increased its position in shares of Advaxis by 28.2% in the 1st quarter. BlackRock Inc. now owns 2,925,417 shares of the biotechnology company’s stock valued at $4,943,000 after purchasing an additional 644,201 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new stake in shares of Advaxis in the 2nd quarter valued at approximately $190,000. LMR Partners LLP purchased a new stake in shares of Advaxis in the 2nd quarter valued at approximately $171,000. Finally, Paloma Partners Management Co purchased a new stake in shares of Advaxis in the 2nd quarter valued at approximately $265,000. 21.32% of the stock is currently owned by hedge funds and other institutional investors.

About Advaxis

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Featured Article: What does earnings per share mean?

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.